Kringle Pharma, Inc. provided earnings guidance for the year ending September 30, 2022. For the year, the company expects net sales of JPY 357 million, operating loss of JPY 497 million, loss of JPY 421 million or JPY 89.24 per basic share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
715 JPY | +0.56% | +6.08% | -4.92% |
1st Jan change | Capi. | |
---|---|---|
-4.92% | 31.05M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- 4884 Stock
- News Kringle Pharma, Inc.
- Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022